CAI:RMDA (Egypt)
Â
Ordinary Shares
E£
2.22
(-6.33%)
Apr 24
Business Description
Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents
ISIN : EGS381B1C015
Share Class Description:
CAI:RMDA: Ordinary SharesCompare
Compare
Traded in other countries / regions
RMDA.Egypt IPO Date
2019-11-27Description
Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents is a pharmaceutical company. The company is engaged in the manufacturing, marketing, selling, and storage of pharmaceutical reagents for both human and veterinary use. It is also involved in manufacturing, marketing, selling, and storing diagnostic and pharmaceutical reagents for human, veterinary, and diagnostic use.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.29 | |||||
| Equity-to-Asset | 0.55 | |||||
| Debt-to-Equity | 0.61 | |||||
| Debt-to-EBITDA | 1.82 | |||||
| Interest Coverage | 2.28 | |||||
| Piotroski F-Score | 3/9 | |||||
| Altman Z-Score | 3.14 | |||||
| Beneish M-Score | -1.62 | |||||
| WACC vs ROIC | ||||||
Growth Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 26.6 | |||||
| 3-Year EBITDA Growth Rate | 26.2 | |||||
| 3-Year EPS without NRI Growth Rate | 32.4 | |||||
| 3-Year FCF Growth Rate | 6.2 | |||||
| 3-Year Book Growth Rate | 15 | |||||
| Future 3-5Y Total Revenue Growth Rate | 29.24 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 13.74 | |||||
| 9-Day RSI | 23.96 | |||||
| 14-Day RSI | 32.25 | |||||
| 6-1 Month Momentum % | 84.35 | |||||
| 12-1 Month Momentum % | 98.14 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.47 | |||||
| Quick Ratio | 1.25 | |||||
| Cash Ratio | 0.23 | |||||
| Days Inventory | 129.35 | |||||
| Days Sales Outstanding | 67.41 | |||||
| Days Payable | 61.7 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | 0.7 | |||||
| Shareholder Yield % | -5.59 |
Profitability Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 47.13 | |||||
| Operating Margin % | 22.7 | |||||
| Net Margin % | 12.74 | |||||
| FCF Margin % | -15.5 | |||||
| ROE % | 14.93 | |||||
| ROA % | 8 | |||||
| ROIC % | 13.96 | |||||
| ROC (Joel Greenblatt) % | 52.47 | |||||
| ROCE % | 30.19 | |||||
| Years of Profitability over Past 10-Year | 6 |
GF Value Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 14.9 | |||||
| PE Ratio without NRI | 14.8 | |||||
| PEG Ratio | 0.76 | |||||
| PS Ratio | 1.74 | |||||
| PB Ratio | 1.88 | |||||
| Price-to-Tangible-Book | 2.82 | |||||
| EV-to-EBIT | 7.85 | |||||
| EV-to-EBITDA | 6.88 | |||||
| EV-to-Forward-EBITDA | 5.11 | |||||
| EV-to-Revenue | 2.12 | |||||
| EV-to-Forward-Revenue | 1.52 | |||||
| EV-to-FCF | -13.67 | |||||
| Price-to-Peter-Lynch-Fair-Value | 0.75 | |||||
| Price-to-Graham-Number | 1.36 | |||||
| Price-to-Net-Current-Asset-Value | 5.84 | |||||
| Earnings Yield (Greenblatt) % | 12.74 | |||||
| FCF Yield % | -9.01 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil E£) | 1,922.351 | ||
| EPS (TTM) (E£) | 0.149 | ||
| Beta | 0 | ||
| Volatility % | 54.48 | ||
| 14-Day RSI | 32.25 | ||
| 14-Day ATR (E£) | 0.18116 | ||
| 20-Day SMA (E£) | 2.621 | ||
| 12-1 Month Momentum % | 98.14 | ||
| 52-Week Range (E£) | 1.307032 - 3.4 | ||
| Shares Outstanding (Mil) | 1,490.53 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents Stock Events
| Event | Date | Price(E£) | ||
|---|---|---|---|---|
| No Event Data | ||||
Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents Frequently Asked Questions
What is Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents(CAI:RMDA)'s stock price today?
The current price of CAI:RMDA is E£2.22. The 52 week high of CAI:RMDA is E£3.40 and 52 week low is E£1.31.
When is next earnings date of Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents(CAI:RMDA)?
The next earnings date of Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents(CAI:RMDA) is .
Does Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents(CAI:RMDA) pay dividends? If so, how much?
Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents(CAI:RMDA) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers